Analysts expect Lion Biotechnologies, Inc. (NASDAQ:IOVA) to post earnings of ($0.35) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Lion Biotechnologies’ earnings. The lowest EPS estimate is ($0.38) and the highest is ($0.29). Lion Biotechnologies reported earnings of ($0.17) per share during the same quarter last year, which indicates a negative year over year growth rate of 105.9%. The business is scheduled to announce its next quarterly earnings report on Friday, November 3rd.
According to Zacks, analysts expect that Lion Biotechnologies will report full year earnings of ($1.42) per share for the current year, with EPS estimates ranging from ($1.48) to ($1.30). For the next financial year, analysts forecast that the firm will report earnings of ($1.45) per share, with EPS estimates ranging from ($1.66) to ($1.23). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Lion Biotechnologies.
A number of equities analysts have weighed in on IOVA shares. Zacks Investment Research upgraded shares of Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Tuesday, July 18th. Oppenheimer Holdings, Inc. started coverage on shares of Lion Biotechnologies in a report on Friday, August 4th. They issued an “outperform” rating and a $13.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Lion Biotechnologies in a report on Wednesday, August 16th. Cowen and Company reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Wednesday, August 16th. Finally, Chardan Capital reiterated a “buy” rating and issued a $20.00 price target on shares of Lion Biotechnologies in a report on Friday, September 1st. Ten investment analysts have rated the stock with a buy rating, Lion Biotechnologies presently has an average rating of “Buy” and a consensus target price of $14.03.
Shares of Lion Biotechnologies (NASDAQ:IOVA) traded down 1.35% during mid-day trading on Thursday, reaching $7.30. The company’s stock had a trading volume of 250,193 shares. Lion Biotechnologies has a 1-year low of $4.45 and a 1-year high of $8.60. The firm’s 50 day moving average price is $7.33 and its 200-day moving average price is $6.46. The company’s market capitalization is $522.15 million.
Hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. purchased a new position in shares of Lion Biotechnologies in the 2nd quarter valued at $19,013,000. Frazier Management LLC purchased a new position in shares of Lion Biotechnologies in the 2nd quarter valued at $15,209,000. Rhumbline Advisers purchased a new position in shares of Lion Biotechnologies in the 2nd quarter valued at $468,000. AXA purchased a new position in shares of Lion Biotechnologies in the 2nd quarter valued at $4,989,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Lion Biotechnologies in the 2nd quarter valued at $380,000. 66.60% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Lion Biotechnologies, Inc. (IOVA) Expected to Announce Earnings of -$0.35 Per Share” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/10/17/lion-biotechnologies-inc-iova-expected-to-announce-earnings-of-0-35-per-share.html.
Lion Biotechnologies Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.